LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Van Hulzen Asset Management LLC

Van Hulzen Asset Management LLC grew its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMATGet Rating) by 24.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,401 shares of the medical instruments supplier’s stock after purchasing an additional 1,842 shares during the period. Van Hulzen Asset Management LLC’s holdings in LeMaitre Vascular were worth $472,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LMAT. BlackRock Inc. boosted its position in shares of LeMaitre Vascular by 5.9% in the third quarter. BlackRock Inc. now owns 3,115,834 shares of the medical instruments supplier’s stock worth $165,420,000 after acquiring an additional 173,671 shares during the last quarter. Copeland Capital Management LLC boosted its position in shares of LeMaitre Vascular by 7.1% in the fourth quarter. Copeland Capital Management LLC now owns 1,205,199 shares of the medical instruments supplier’s stock worth $60,537,000 after acquiring an additional 80,112 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of LeMaitre Vascular by 123.8% in the third quarter. Renaissance Technologies LLC now owns 103,500 shares of the medical instruments supplier’s stock worth $5,495,000 after acquiring an additional 57,261 shares during the last quarter. Citadel Advisors LLC boosted its position in shares of LeMaitre Vascular by 151.0% in the third quarter. Citadel Advisors LLC now owns 65,924 shares of the medical instruments supplier’s stock worth $3,500,000 after acquiring an additional 39,655 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of LeMaitre Vascular by 13.3% in the third quarter. Russell Investments Group Ltd. now owns 308,539 shares of the medical instruments supplier’s stock worth $16,379,000 after acquiring an additional 36,121 shares during the last quarter. 85.82% of the stock is currently owned by institutional investors and hedge funds.

Shares of LMAT traded up $1.79 during mid-day trading on Tuesday, reaching $47.61. 1,610 shares of the stock traded hands, compared to its average volume of 109,386. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of 36.37, a price-to-earnings-growth ratio of 3.34 and a beta of 1.32. The firm has a fifty day moving average of $45.24. LeMaitre Vascular, Inc. has a 12-month low of $39.48 and a 12-month high of $64.50.

LeMaitre Vascular (NASDAQ:LMATGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The medical instruments supplier reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.03). The firm had revenue of $39.50 million for the quarter, compared to analysts’ expectations of $39.70 million. LeMaitre Vascular had a net margin of 17.42% and a return on equity of 12.42%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.34 EPS. As a group, analysts predict that LeMaitre Vascular, Inc. will post 1.39 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 24th. Stockholders of record on Tuesday, March 8th were paid a dividend of $0.125 per share. The ex-dividend date was Monday, March 7th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 1.05%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.11. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 39.68%.

LMAT has been the topic of a number of recent research reports. Zacks Investment Research raised shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a research report on Wednesday, March 2nd. StockNews.com initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Finally, Barrington Research reduced their price target on shares of LeMaitre Vascular from $62.00 to $54.00 in a research report on Friday, February 25th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular has an average rating of “Buy” and a consensus target price of $61.80.

In related news, insider Trent G. Kamke sold 7,929 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $48.22, for a total value of $382,336.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 14.10% of the company’s stock.

LeMaitre Vascular Company Profile (Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Featured Stories

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMATGet Rating).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.